Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer

Pembrolizumab, or anti-programmed death receptor 1 antibody, is an immune checkpoint inhibitor that can cause immune-related adverse events. We herein report for the first time the progression of hypopituitarism and hypothyroidism after treatment with pembrolizumab in a patient with adrenal metastas...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Intern Med
Autors principals: Yamagata, Satoshi, Kageyama, Kazunori, Takayasu, Shinobu, Asari, Yuko, Makita, Koshi, Terui, Ken, Daimon, Makoto
Format: Artigo
Idioma:Inglês
Publicat: The Japanese Society of Internal Medicine 2019
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6949454/
https://ncbi.nlm.nih.gov/pubmed/31462588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.3008-19
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars